Salarius Pharmaceuticals Statistics
Total Valuation
SLRX has a market cap or net worth of $2.94 million. The enterprise value is $1.92 million.
Market Cap | 2.94M |
Enterprise Value | 1.92M |
Important Dates
The last earnings date was Tuesday, August 12, 2025, after market close.
Earnings Date | Aug 12, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
SLRX has 509,706 shares outstanding.
Current Share Class | 509,706 |
Shares Outstanding | 509,706 |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.14% |
Owned by Institutions (%) | 2.54% |
Float | 508,990 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.61
Current Ratio | 0.61 |
Quick Ratio | 0.36 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -660.37% and return on invested capital (ROIC) is -459.32%.
Return on Equity (ROE) | -660.37% |
Return on Assets (ROA) | -143.52% |
Return on Invested Capital (ROIC) | -459.32% |
Return on Capital Employed (ROCE) | 684.50% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.55M |
Employee Count | 2 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.53% in the last 52 weeks. The beta is 0.45, so SLRX's price volatility has been lower than the market average.
Beta (5Y) | 0.45 |
52-Week Price Change | -80.53% |
50-Day Moving Average | 10.75 |
200-Day Moving Average | 17.17 |
Relative Strength Index (RSI) | 35.08 |
Average Volume (20 Days) | 432,711 |
Short Selling Information
Short Interest | 803,608 |
Short Previous Month | 678,491 |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.16 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -5.68M |
Pretax Income | -6.46M |
Net Income | -5.10M |
EBITDA | -5.68M |
EBIT | -5.68M |
Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has $794,886 in cash and n/a in debt, giving a net cash position of $794,886 or $1.56 per share.
Cash & Cash Equivalents | 794,886 |
Total Debt | n/a |
Net Cash | 794,886 |
Net Cash Per Share | $1.56 |
Equity (Book Value) | -829,724 |
Book Value Per Share | n/a |
Working Capital | -862,924 |
Cash Flow
Operating Cash Flow | -4.14M |
Capital Expenditures | n/a |
Free Cash Flow | -4.14M |
FCF Per Share | -$8.13 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
SLRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -188.20% |
FCF Yield | -152.79% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on August 18, 2025. It was a reverse split with a ratio of 1:15.
Last Split Date | Aug 18, 2025 |
Split Type | Reverse |
Split Ratio | 1:15 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |